Molecularly Targeted Clinical Trials

被引：6

作者：

Smith-Cohn, Matthew A. ^{[1
,2
]}

Celiku, Orieta ^{[3
]}

Gilbert, Mark R. ^{[3
]}

机构：

[1] NCI, Neurooncol Branch, NIH, 37 Convent Dr,Bldg 37,Room 1016, Bethesda, MD 20892 USA

[2] Johns Hopkins Univ, Dept Neurol, Sch Med, Baltimore, MD 21287 USA

[3] NCI, Neurooncol Branch, NIH, 37 Convent Dr,Bldg 37,Room 1142, Bethesda, MD 20892 USA

来源：

NEUROSURGERY CLINICS OF NORTH AMERICA | 2021年 / 32卷 / 02期

关键词：

Glioblastoma; Heterogenicity; Targeted therapy; Blood-brain barrier; Synthetic lethality; SYNTHETIC LETHAL INTERACTIONS; MGMT PROMOTER METHYLATION; CENTRAL-NERVOUS-SYSTEM; PREDICTIVE-VALUE; PRIMARY BRAIN; CANCER; TUMORS; GLIOBLASTOMA; TEMOZOLOMIDE; CHEMOTHERAPY;

D O I：

10.1016/j.nec.2020.12.002

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Glioblastoma remains incurable despite advances in surgery, radiation, and chemotherapy, underscoring the need for new therapies. The genetic heterogenicity, presence of redundant molecular pathways, and the blood-brain barrier have limited the applicability of molecularly targeted agents. The therapeutic benefit seen with a small subset of patients suggests, however, that patient selection is critical. Recent investigations show that molecularly targeted synthetic lethality is a promising complementary approach. The article provides an overview of the challenges of molecularly targeted therapy in adults with glioblastoma, including current trials and future therapeutic directions. © 2020

引用

页码：191 / 210

页数：20

共 66 条

[1] Prolonged disease control with MEK inhibitor in neurofibromatosis type I-associated glioblastoma [J].

Ameratunga, M. ;

McArthur, G. ;

Gan, H. ;

Cher, L. .

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2016, 41 (03) :357-359

[2] Synthetic lethal therapies for cancer: what's next after PARP inhibitors? [J].

Ashworth, Alan ;

Lord, Christopher J. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (09) :564-576

[3] Brain tumors in Sweden: Data from a population-based registry 1999-2012 [J].

Asklund, Thomas ;

Malmstrom, Annika ;

Bergqvist, Michael ;

Bjor, Ove ;

Henriksson, Roger .

ACTA ONCOLOGICA, 2015, 54 (03) :377-384

[4] Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 [J].

Barbie, David A. ;

Tamayo, Pablo ;

Boehm, Jesse S. ;

Kim, So Young ;

Moody, Susan E. ;

Dunn, Ian F. ;

Schinzel, Anna C. ;

Sandy, Peter ;

Meylan, Etienne ;

Scholl, Claudia ;

Froehling, Stefan ;

Chan, Edmond M. ;

Sos, Martin L. ;

Michel, Kathrin ;

Mermel, Craig ;

Silver, Serena J. ;

Weir, Barbara A. ;

Reiling, Jan H. ;

Sheng, Qing ;

Gupta, Piyush B. ;

Wadlow, Raymond C. ;

Le, Hanh ;

Hoersch, Sebastian ;

Wittner, Ben S. ;

Ramaswamy, Sridhar ;

Livingston, David M. ;

Sabatini, David M. ;

Meyerson, Matthew ;

Thomas, Roman K. ;

Lander, Eric S. ;

Mesirov, Jill P. ;

Root, David E. ;

Gilliland, D. Gary ;

Jacks, Tyler ;

Hahn, William C. .

NATURE, 2009, 462 (7269) :108-U122

[5] Antiangiogenic Therapy for Glioblastoma: Current Status and Future Prospects [J].

Batchelor, Tracy T. ;

Reardon, David A. ;

de Groot, John F. ;

Wick, Wolfgang ;

Weller, Michael .

CLINICAL CANCER RESEARCH, 2014, 20 (22) :5612-5619

[6]

Baudino Troy A, 2015, Curr Drug Discov Technol, V12, P3

[7] Recurrent MET fusion genes represent a drug target in pediatric glioblastoma [J].

Bender, Sebastian ;

Gronych, Jan ;

Warnatz, Hans-Joerg ;

Hutter, Barbara ;

Groebner, Susanne ;

Ryzhova, Marina ;

Pfaff, Elke ;

Hovestadt, Volker ;

Weinberg, Florian ;

Halbach, Sebastian ;

Kool, Marcel ;

Northcott, Paul A. ;

Sturm, Dominik ;

Bjerke, Lynn ;

Zichner, Thomas ;

Stutz, Adrian M. ;

Schramm, Kathrin ;

Huang, Bingding ;

Buchhalter, Ivo ;

Heinold, Michael ;

Risch, Thomas ;

Worst, Barbara C. ;

van Tilburg, Cornelis M. ;

Weber, Ursula D. ;

Zapatka, Marc ;

Raeder, Benjamin ;

Milford, David ;

Heiland, Sabine ;

von Kalle, Christof ;

Previti, Christopher ;

Lawerenz, Chris ;

Kulozik, Andreas E. ;

Unterberg, Andreas ;

Witt, Olaf ;

von Deimling, Andreas ;

Capper, David ;

Truffaux, Nathalene ;

Grill, Jacques ;

Jabado, Nada ;

Sehested, Astrid M. ;

Sumerauer, David ;

Hmida-Ben Brahim, Dorra ;

Trabelsi, Saoussen ;

Ng, Ho-Keung ;

Zagzag, David ;

Allen, Jeffrey C. ;

Karajannis, Matthias A. ;

Gottardo, Nicholas G. ;

Jones, Chris ;

Korbel, Jan .

NATURE MEDICINE, 2016, 22 (11) :1314-1320

[8] The Somatic Genomic Landscape of Glioblastoma [J].

Brennan, Cameron W. ;

Verhaak, Roel G. W. ;

McKenna, Aaron ;

Campos, Benito ;

Noushmehr, Houtan ;

Salama, Sofie R. ;

Zheng, Siyuan ;

Chakravarty, Debyani ;

Sanborn, J. Zachary ;

Berman, Samuel H. ;

Beroukhim, Rameen ;

Bernard, Brady ;

Wu, Chang-Jiun ;

Genovese, Giannicola ;

Shmulevich, Ilya ;

Barnholtz-Sloan, Jill ;

Zou, Lihua ;

Vegesna, Rahulsimham ;

Shukla, Sachet A. ;

Ciriello, Giovanni ;

Yung, W. K. ;

Zhang, Wei ;

Sougnez, Carrie ;

Mikkelsen, Tom ;

Aldape, Kenneth ;

Bigner, Darell D. ;

Van Meir, Erwin G. ;

Prados, Michael ;

Sloan, Andrew ;

Black, Keith L. ;

Eschbacher, Jennifer ;

Finocchiaro, Gaetano ;

Friedman, William ;

Andrews, David W. ;

Guha, Abhijit ;

Iacocca, Mary ;

O'Neill, Brian P. ;

Foltz, Greg ;

Myers, Jerome ;

Weisenberger, Daniel J. ;

Penny, Robert ;

Kucherlapati, Raju ;

Perou, Charles M. ;

Hayes, D. Neil ;

Gibbs, Richard ;

Marra, Marco ;

Mills, Gordon B. ;

Lander, Eric ;

Spellman, Paul ;

Wilson, Richard .

CELL, 2013, 155 (02) :462-477

[9] The origin of variations in sexual and sex-limited characters [J].

Bridges, CB .

AMERICAN NATURALIST, 1922, 56 :51-63

[10] Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase [J].

Bryant, HE ;

Schultz, N ;

Thomas, HD ;

Parker, KM ;

Flower, D ;

Lopez, E ;

Kyle, S ;

Meuth, M ;

Curtin, NJ ;

Helleday, T .

NATURE, 2005, 434 (7035) :913-917

← 1 2 3 4 5 6 7 →